GLP-1 RA use associated with higher prevalence of residual gastric content in participants undergoing elective procedure under anesthesia<\/p>\n<\/h3>\n
By Elana Gotkine HealthDay Reporter<\/b><\/p>\n
<\/b><\/p>\n
TUESDAY, March 12, 2024 (HealthDay News) — Use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) is associated with a higher prevalence of increased residual gastric content (RGC), according to a study published online March 6 in JAMA Surgery<\/em>.<\/p>\n Sudipta Sen, M.D., from McGovern Medical School at The University of Texas Health Science Center at Houston, and colleagues examined the association between use of once-weekly GLP-1 RAs and the prevalence of increased RGC, a risk factor for aspiration under anesthesia, using gastric ultrasonography in a cross-sectional study. Before undergoing an elective procedure under anesthesia, participants followed preprocedural fasting guidelines.<\/p>\n The researchers found that the prevalence of increased RGC was 56 percent among the 62 patients with GLP-1 RA use (exposure group) compared with 19 percent in the 62 patients not taking a GLP-1 RA drug (control group). GLP-1 RA use was associated with a 30.5 percent higher prevalence of increased RGC after adjustment for confounding (adjusted prevalence ratio, 2.48). No association was seen between the duration of GLP-1 RA interruption and prevalence of increased RGC.<\/p>\n “Our study fills a significant gap in the current understanding and management of patients on GLP-1 RAs undergoing surgery,” senior author Omonele O. Nwokolo, M.D., also from McGovern Medical School, said in a statement. “The lack of data had previously led societies to rely on expert opinion for guidance. Our evidence paves the way for informed guidelines and further research to mitigate anesthesia-related risks in this patient population.”<\/p>\n Abstract\/Full Text (subscription or payment may be required)\u00a0<\/a><\/p>\n <\/i><\/p>\n